ObjectivesRedistributive health policies aim to orchestrate welfare distribution in response to the needs of the underprivileged sections of society. Turkey has undertaken a massive pharmaceutical price reform since 2009 to show a more appealing, positive side to its citizens. This investigation examines the welfare implications of pharmaceutical price reductions on Turkish households. MethodsData from the Turkish Statistical Institute, pertaining to the national household budget survey for 2003, 2009, 2015, and 2019, were collected and analyzed. Difference-in-difference estimators combined with propensity score matching were applied to repeated cross-sectional microdata to evaluate the impact of strict pharmaceutical price policy on households’ out-of-pocket (OOP) pharmaceutical expenditures. ResultsThe Kakwani index and the Lorenz and concentration curves revealed a coherently regressive pattern and highlighted that vulnerable groups shoulder the burden of pharmaceutical expenditures (KW2003 = −0.49; KW2009 = −0.61; KW2015 = −0.62; KW2019 = −0.52). Because of the positive and significant interaction parameter obtained from caliper matching (0.06090, P < 0.05), the increase in OOP pharmaceutical expenditure is high in households with catastrophic OOP health expenditure. ConclusionsThe effective use of fiscal capacity, the continual monitoring of the household poverty effect of pharmaceutical price reductions, and the groundwork for a developmental pharmaceutical sector industrial policy agenda are imperative to disseminating the benefits of universal health coverage and constructing rationally conceived inclusive policies.